Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QY201 in moderate to severe atopic dermatitis
NCT07180511Phase 3Enrolling by invitation
- Sponsor
- E-nitiate
- Start
- Mar 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of qy201 in atopic dermatitis (AD) (3 arms), sponsored by E-nitiate. Primary endpoints: Proportion of subjects who achieved EASI-75 at 16 weeks and Proportion of subjects who achieved vIGA-AD 0/1 with a reduction of >=2 points at 16 weeks. Started Mar 2025; status: enrolling by invitation.
02
Drugs
qy201
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07180511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07180511.